(firstQuint)Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma.

 Description Patients who fulfill eligibility criteria will be entered into the trial to receive tremelimumab and MEDI3617.

 After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle.

 The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have melanoma, not everyone who participates in this research study will receive the same dose of the study drug.

 The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.

 - Tremelimumab - MEDI3617.

 Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma@highlight

This is an open label, phase I trial, testing the combination of Tremelimumab and MEDI3617 in patients with metastatic melanoma.

